APA (7th ed.) Citation

Suzuki, M., Uchibori, K., Oh-hara, T., Nomura, Y., Suzuki, R., Takemoto, A., . . . Katayama, R. (2024). A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer. npj Precision Oncology, 8(1), . https://doi.org/10.1038/s41698-024-00542-9

Chicago Style (17th ed.) Citation

Suzuki, Mai, et al. "A Macrocyclic Kinase Inhibitor Overcomes Triple Resistant Mutations in EGFR-positive Lung Cancer." Npj Precision Oncology 8, no. 1 (2024). https://doi.org/10.1038/s41698-024-00542-9.

MLA (9th ed.) Citation

Suzuki, Mai, et al. "A Macrocyclic Kinase Inhibitor Overcomes Triple Resistant Mutations in EGFR-positive Lung Cancer." Npj Precision Oncology, vol. 8, no. 1, 2024, https://doi.org/10.1038/s41698-024-00542-9.